For both induction and maintenance therapy, subcutaneous guselkumab significantly improves clinical outcomes in patients with ...
Recommendation based on the findings from the Phase 3 QUASAR programme in ulcerative colitis 1. Beerse, Belgium (28 February 2025) - Johnson & Johnson today announced that the Com ...
Findings were announced from a phase 3 trial evaluating guselkumab subcutaneous (SC) induction therapy in patients with moderately to severely active ulcerative colitis (UC). Study participants ...
Tremfya could become the first IL-23 inhibitor with fully subcutaneous induction and maintenance options in the treatment of ...
J&J announces positive data from phase 3 ASTRO study of Tremfya SC induction therapy in adults with moderately to severely active ulcerative colitis: Spring House, Pennsylvania Mo ...
Johnson & Johnson (J&J) has shared positive results from a late-stage study evaluating a subcutaneous (SC) version of Tremfya ...
GlobalData on MSN10d
J&J’s fully subcutaneous Tremfya shows 27.6% clinical remission in UCTremfya was administered subcutaneously for both induction and maintenance, inducing a clinical response in 65% of moderate to severe UC patients.
US healthcare giant Johnson & Johnson has announced data from the Phase III ASTRO study of Tremfya (guselkumab) subcutaneous (SC) induction therapy in adults with moderately to severely active ...
Medpage Today on MSN13d
Some Psoriasis Biologics Better Than Others for Preventing Progression to PsAPsoriasis was less likely to progress to psoriatic arthritis (PsA) among patients treated with interleukin-17 (IL-17) or ...
GlobalData on MSN7d
OSE’s UC therapy prompts 16% clinical remission after ten weeksThe CoTikiS trial’s ten-week results from the 50-week trial saw as an endoscopic improvement rate of 32% in patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback